Related Experiment Videos
Immunosuppression in liver transplantation.
G T Everson1, J F Trotter, M Kugelmas
1Division of Gastroenterology and Hepatology and Department of Medicine, University of Colorado School of Medicine, Denver, CO 80262, USA. greg.overson@uchsc.edu
Minerva Chirurgica
|November 7, 2003
Summary
Immunosuppressive drugs effectively prevent liver transplant rejection but have side effects. Strategies like calcineurin-sparing regimens and steroid withdrawal can mitigate complications and improve outcomes for liver recipients.
Area of Science:
- Immunology
- Pharmacology
- Transplantation Medicine
Background:
- Liver allograft rejection poses a significant risk to graft survival and patient mortality.
- Current immunosuppressive medications are crucial for preventing rejection but are associated with dose-dependent side effects.
- Calcineurin inhibitors (Cyclosporine, Tacrolimus) form the cornerstone of maintenance immunosuppression, often requiring modification to manage metabolic complications.
Purpose of the Study:
- To review currently available immunosuppressive medications for hepatic allograft rejection.
- To discuss strategies for managing side effects and optimizing immunosuppression.
- To explore the impact of immunosuppression on post-transplant hepatitis C recurrence.
Main Methods:
- Review of current literature on immunosuppressive medications in liver transplantation.
- Analysis of strategies for managing drug toxicity and complications.
- Discussion of approaches to post-transplant hepatitis C management.
Main Results:
- Immunosuppressive medications are highly effective in preventing rejection, graft loss, and death.
- Steroid withdrawal can ameliorate toxic effects without increasing rejection risk.
- Calcineurin-sparing regimens (e.g., mycophenolate mofetil, sirolimus) allow for reduced calcineurin inhibitor doses.
- Hepatitis C recurrence post-transplant is universal and aggressive, with no definitive immunosuppressive strategy proven to modify its course.
Conclusions:
- Tailoring immunosuppressive prescriptions based on ongoing advances in medications is essential for liver transplant recipients.
- Managing side effects and addressing hepatitis C recurrence are key challenges in long-term liver transplant care.
- Future developments in immunosuppressive and antiviral therapies hold promise for improved patient outcomes.